Sanofi took the opportunity at the American Diabetes Association (ADA) 78th Scientific Sessions in Florida to unveil new data on its diabetes therapy Toujeo (insulin glargine 300 units.mL), demonstrating that it proved non-inferior to insulin degludec in adult patients with type 2 diabetes who were not previously on insulin.
Ook interessant voor je
Reageer